US biopharma: "nearly 300 vaccines in R&D"

Article Date: 24/04/2012 06:00
US biopharma: "nearly 300 vaccines in R&D"

Vacancy Search

Quick job search

Advanced Search

Latest News

Interview – Overnight sensation Intercept settles down for hard yards

Ask Intercept Pharmaceuticals chief executive Mark Pruzanski whether he expected his company to become the poster child of the biotech bull market, and he will say it took him off guard.

Back to the drawing board for Boehringer and Presidio in hep C

Just how tough competing in hepatitis C has become is perfectly illustrated by Boehringer Ingelheim’s exit from the hottest part of this space in March, and the group has recently put more...

End of the road for Cytos after asthma flop

End of the road for Cytos after asthma flop

England's NHS: performance gap with rest of the UK "is narrowing"

England's NHS: performance gap with rest of the UK "is narrowing"

New hep C drugs prices 'as breathtaking as effectiveness'

New hep C drugs prices 'as breathtaking as effectiveness'

J&J drops Botox rival

J&J drops Botox rival

Extra hours, Skype check-ups for 7m patients

Extra hours, Skype check-ups for 7m patients

GSK in dock again over Poland bribery allegations: UPDATED

GSK in dock again over Poland bribery allegations: UPDATED

Lombard postpones IPO as US indices decline

It is hard to know what to make of the IPO scene in medtech. In recent months companies have been unusually keen to file for initial offerings, and some, such as Tandem Diabetes Care and...

As US adcoms fall, FDA free thinking rises

Volatility around US FDA advisory committee meetings provides remarkable opportunities for bio run-up trading, and those following this strategy will find it vital to stay abreast of the...
more news